Ontology type: schema:ScholarlyArticle Open Access: True
2018-02-22
AUTHORSDavid M. Ross, Tamas Masszi, María Teresa Gómez Casares, Andrzej Hellmann, Jesper Stentoft, Eibhlin Conneally, Valentin Garcia-Gutierrez, Norbert Gattermann, Philipp D. le Coutre, Bruno Martino, Susanne Saussele, Francis J. Giles, Jerald P. Radich, Giuseppe Saglio, Weiping Deng, Nancy Krunic, Véronique Bédoucha, Prashanth Gopalakrishna, Andreas Hochhaus
ABSTRACTPurposeENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.MethodsAttempting TFR required ≥ 3 years of nilotinib, a molecular response of MR4.5 [BCR-ABL1 ≤ 0.0032% on the International Scale (BCR-ABL1IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1IS ≤ 0.1%).ResultsNinety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with ≥ 1 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS ≤ 0.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.ConclusionsThese results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR. More... »
PAGES945-954
http://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x
DOIhttp://dx.doi.org/10.1007/s00432-018-2604-x
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1101145018
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29468438
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Kaplan-Meier Estimate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein-Tyrosine Kinases",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Pyrimidines",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Remission Induction",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Time Factors",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Haematology, SA Pathology, Room 6E359, Royal Adelaide Hospital, 1 Port Rd, 5000, Adelaide, SA, Australia",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Division of Haematology, SA Pathology, Room 6E359, Royal Adelaide Hospital, 1 Port Rd, 5000, Adelaide, SA, Australia"
],
"type": "Organization"
},
"familyName": "Ross",
"givenName": "David M.",
"id": "sg:person.01110323637.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110323637.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Semmelweis University, Budapest, Hungary",
"id": "http://www.grid.ac/institutes/grid.11804.3c",
"name": [
"Semmelweis University, Budapest, Hungary"
],
"type": "Organization"
},
"familyName": "Masszi",
"givenName": "Tamas",
"id": "sg:person.0751651512.21",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751651512.21"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain",
"id": "http://www.grid.ac/institutes/grid.411250.3",
"name": [
"Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain"
],
"type": "Organization"
},
"familyName": "G\u00f3mez Casares",
"givenName": "Mar\u00eda Teresa",
"id": "sg:person.0716710447.44",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716710447.44"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical University of Gda\u0144sk, Gda\u0144sk, Poland",
"id": "http://www.grid.ac/institutes/grid.11451.30",
"name": [
"Medical University of Gda\u0144sk, Gda\u0144sk, Poland"
],
"type": "Organization"
},
"familyName": "Hellmann",
"givenName": "Andrzej",
"id": "sg:person.01154416326.31",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154416326.31"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Aarhus University Hospital, Aarhus, Denmark",
"id": "http://www.grid.ac/institutes/grid.154185.c",
"name": [
"Aarhus University Hospital, Aarhus, Denmark"
],
"type": "Organization"
},
"familyName": "Stentoft",
"givenName": "Jesper",
"id": "sg:person.016036621425.38",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016036621425.38"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "St James\u2019s Hospital, Dublin, Ireland",
"id": "http://www.grid.ac/institutes/grid.416409.e",
"name": [
"St James\u2019s Hospital, Dublin, Ireland"
],
"type": "Organization"
},
"familyName": "Conneally",
"givenName": "Eibhlin",
"id": "sg:person.01132647406.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01132647406.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain",
"id": "http://www.grid.ac/institutes/grid.411347.4",
"name": [
"Hospital Universitario Ram\u00f3n y Cajal, IRYCIS, Madrid, Spain"
],
"type": "Organization"
},
"familyName": "Garcia-Gutierrez",
"givenName": "Valentin",
"id": "sg:person.01322203274.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322203274.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.14778.3d",
"name": [
"Universit\u00e4tsklinikum D\u00fcsseldorf, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "Norbert",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany",
"id": "http://www.grid.ac/institutes/grid.6363.0",
"name": [
"Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany"
],
"type": "Organization"
},
"familyName": "le Coutre",
"givenName": "Philipp D.",
"id": "sg:person.01344447222.75",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344447222.75"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy",
"id": "http://www.grid.ac/institutes/grid.414504.0",
"name": [
"Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy"
],
"type": "Organization"
},
"familyName": "Martino",
"givenName": "Bruno",
"id": "sg:person.01105522434.09",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105522434.09"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany",
"id": "http://www.grid.ac/institutes/grid.7700.0",
"name": [
"III. Med. Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany"
],
"type": "Organization"
},
"familyName": "Saussele",
"givenName": "Susanne",
"id": "sg:person.0611020122.69",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611020122.69"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Developmental Therapeutics Consortium, Chicago, IL, USA",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Developmental Therapeutics Consortium, Chicago, IL, USA"
],
"type": "Organization"
},
"familyName": "Giles",
"givenName": "Francis J.",
"id": "sg:person.011165370517.24",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011165370517.24"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA",
"id": "http://www.grid.ac/institutes/grid.270240.3",
"name": [
"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA"
],
"type": "Organization"
},
"familyName": "Radich",
"givenName": "Jerald P.",
"id": "sg:person.011362420057.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011362420057.85"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "University of Turin, Orbassano, Italy",
"id": "http://www.grid.ac/institutes/grid.7605.4",
"name": [
"University of Turin, Orbassano, Italy"
],
"type": "Organization"
},
"familyName": "Saglio",
"givenName": "Giuseppe",
"id": "sg:person.01334477453.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334477453.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.418424.f",
"name": [
"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
],
"type": "Organization"
},
"familyName": "Deng",
"givenName": "Weiping",
"id": "sg:person.01217254625.41",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217254625.41"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Institutes for BioMedical Research, Cambridge, MA, USA",
"id": "http://www.grid.ac/institutes/grid.418424.f",
"name": [
"Novartis Institutes for BioMedical Research, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Krunic",
"givenName": "Nancy",
"id": "sg:person.016402170507.13",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016402170507.13"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharma AG, Basel, Switzerland",
"id": "http://www.grid.ac/institutes/grid.419481.1",
"name": [
"Novartis Pharma AG, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "B\u00e9doucha",
"givenName": "V\u00e9ronique",
"id": "sg:person.0761205252.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761205252.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Novartis Pharma AG, Basel, Switzerland",
"id": "http://www.grid.ac/institutes/grid.419481.1",
"name": [
"Novartis Pharma AG, Basel, Switzerland"
],
"type": "Organization"
},
"familyName": "Gopalakrishna",
"givenName": "Prashanth",
"id": "sg:person.0770232473.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770232473.03"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Abteilung H\u00e4matologie/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany",
"id": "http://www.grid.ac/institutes/grid.275559.9",
"name": [
"Abteilung H\u00e4matologie/Onkologie, Universit\u00e4tsklinikum Jena, Jena, Germany"
],
"type": "Organization"
},
"familyName": "Hochhaus",
"givenName": "Andreas",
"id": "sg:person.01064615503.48",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064615503.48"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/leu.2016.115",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022073613",
"https://doi.org/10.1038/leu.2016.115"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00432-016-2159-7",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050966069",
"https://doi.org/10.1007/s00432-016-2159-7"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2017.63",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1083850241",
"https://doi.org/10.1038/leu.2017.63"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/leu.2016.5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1041273297",
"https://doi.org/10.1038/leu.2016.5"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-02-22",
"datePublishedReg": "2018-02-22",
"description": "PurposeENESTfreedom is evaluating treatment-free remission (TFR) following frontline nilotinib in patients with chronic myeloid leukemia (CML) in chronic phase. Following our primary analysis at 48 weeks, we here provide an updated 96-week analysis.MethodsAttempting TFR required\u2009\u2265\u20093\u00a0years of nilotinib, a molecular response of MR4.5 [BCR-ABL1\u2009\u2264\u20090.0032% on the International Scale (BCR-ABL1IS)], and sustained deep molecular response (DMR) during a 1-year consolidation phase. Patients restarted nilotinib following loss of major molecular response (MMR; BCR-ABL1IS\u2009\u2264\u20090.1%).ResultsNinety-six weeks after stopping treatment (3.6-year median prior nilotinib duration), 93 of 190 patients (48.9%) remained in TFR. Of 88 patients who restarted nilotinib following loss of MMR, 87 regained MMR and 81 regained MR4.5 by the data cut-off. Ninety-six-week TFR rates were 61.3, 50.0, and 28.6% in patients with low, intermediate, and high Sokal risk scores at diagnosis, respectively. Patients consistently in MR4.5 during consolidation had higher TFR rates (50.6%) than patients with \u2265\u20091 assessment without MR4.5 during consolidation (35.0%). In a landmark analysis, 96-week TFR rates for patients with MR4.5, MR4 (BCR-ABL1IS\u2009\u2264\u20090.01%) but not MR4.5, and MMR but not MR4 at TFR week 12 were 82.6, 23.1, and 0%, respectively. There were no reports of disease progression or death due to CML; overall adverse event frequency decreased following TFR. Within the follow-up period, TFR did not adversely affect disease outcomes.ConclusionsThese results demonstrate the feasibility and durability of TFR following frontline nilotinib and emphasize the importance of sustained DMR for TFR.",
"genre": "article",
"id": "sg:pub.10.1007/s00432-018-2604-x",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1313647",
"issn": [
"0171-5216",
"1432-1335"
],
"name": "Journal of Cancer Research and Clinical Oncology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "5",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "144"
}
],
"keywords": [
"treatment-free remission",
"chronic myeloid leukemia",
"deep molecular response",
"frontline nilotinib",
"TFR rate",
"chronic phase",
"myeloid leukemia",
"high Sokal risk scores",
"overall adverse event frequency",
"sustained deep molecular response",
"durable treatment-free remission",
"Sokal risk score",
"higher TFR rates",
"major molecular response",
"adverse event frequency",
"molecular response",
"loss of MMR",
"week 12",
"disease progression",
"landmark analysis",
"disease outcome",
"MR4.5",
"risk score",
"patients",
"primary analysis",
"nilotinib",
"ConclusionsThese results",
"remission",
"leukemia",
"MMR",
"weeks",
"consolidation phase",
"response",
"MR4",
"diagnosis",
"progression",
"death",
"outcomes",
"rate",
"treatment",
"scores",
"event frequency",
"report",
"loss",
"years",
"assessment",
"period",
"analysis",
"study",
"consolidation",
"update",
"frequency",
"data",
"feasibility",
"importance",
"phase",
"results",
"durability"
],
"name": "Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study",
"pagination": "945-954",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1101145018"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00432-018-2604-x"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29468438"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00432-018-2604-x",
"https://app.dimensions.ai/details/publication/pub.1101145018"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:07",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_780.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00432-018-2604-x"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00432-018-2604-x'
This table displays all metadata directly associated to this object as RDF triples.
370 TRIPLES
21 PREDICATES
102 URIs
90 LITERALS
22 BLANK NODES